Chemotherapy Dose Reductions in Palliative Lung Cancer V1.0
Research type
Research Study
Full title
Dose Reductions in Palliative Lung Cancer following an episode of Neutropenia
IRAS ID
242100
Contact name
Khuram Moaz Ahmad Amini
Contact email
Duration of Study in the UK
0 years, 6 months, 1 days
Research summary
Chemotherapy Induced Neutropenia (CIN) is a well known phenomenon among cancer patients. It poses a significant risk to patients who are more susceptible to opportunistic infections and thus morbidity and mortality. Approximately 50% of patients with a previous history CIN often relapse to a futher episode of neutropenia. It is often managed by using supportive medication like Granulocyte-colony-stimulating-factors (G-CSF), which boost the neutrophil count or applying dose reduction to the chemotherapy. In palliative cancer, G-CSF use is restricted as patients may still relapse to further episodes of neutropenia.
Evidence suggests that neutropenia is dose related to the chemotherapy and thus an adequate dose reduction can prevent a further episode. However, dose reductions are often dependent on clinicians judgement rather than any clinical evidence or rationale. This has led to an inconstant approach in chemotherapy dose reductions and thus a variation in patient outcome. Lung cancer patients have a high incidence of CIN and subsequently often require a dose reduction. Evaluating the factors responsible for increasing the risk of neutropenia and dose reducing appropriately, will lower further incidences of neutropenia. This will reduce neutropenia related hospital admissions and also improve patient outcome by reducing chemotherapy delays.
This is a retrospective analysis and will analyse patient factors in conjunction with the applied dose reduction in preventing a further episode of neutropenia.
REC name
Yorkshire & The Humber - Bradford Leeds Research Ethics Committee
REC reference
18/YH/0478
Date of REC Opinion
19 Dec 2018
REC opinion
Favourable Opinion